title: Epilepsy and pregnancy: lamotrigine as main drug used.
abstract: OBJECTIVE
  To study the risk of teratogenicity in infants of women with epilepsy.
  
  
  METHODS
  Prospective data from 1996 to 2000 comprised 147 pregnancies. The most frequent antiepileptic drugs (AEDs) used were lamotrigine (LTG) 35% (n = 51), oxcarbazepine (OXC) 25% (n = 37) and valproate (VPA) 20% (n = 30). Seventy-four per cent (n = 109) received monotherapy. Folic acid supplementation was taken during first trimester by 118 patients (80%).
  
  
  RESULTS
  The overall risk of malformations among newborns in the AED-exposed group was 3.1% (n = 4). Two children were born with multiple malformations (VPA monotherapy), two children had ventricular septal defects (one OXC monotherapy, and one OXC and LTG). The risk of malformations was 2.0% in women treated with LTG and 6.7% in women treated with VPA (NS).
  
  
  CONCLUSIONS
  Despite the small number of cases in the study these data indicate that treatment with LTG during pregnancy might be relatively safe. Larger prospective studies are needed to obtain adequate power for statistical analysis.
authors.affiliation: Danish Epilepsy Hospital, Dianalund, Denmark. anns@glostruphosp.kbhamt.dk
authors.forename: A
authors.initials: A
authors.lastname: Sabers
authors.forename: M
authors.initials: M
authors.lastname: Dam
authors.forename: B
authors.initials: B
authors.lastname: A-Rogvi-Hansen
authors.forename: J
authors.initials: J
authors.lastname: Boas
authors.forename: P
authors.initials: P
authors.lastname: Sidenius
authors.forename: M
authors.initials: M
authors.lastname: Laue Friis
authors.forename: J
authors.initials: J
authors.lastname: Alving
authors.forename: M
authors.initials: M
authors.lastname: Dahl
authors.forename: J
authors.initials: J
authors.lastname: Ankerhus
authors.forename: A
authors.initials: A
authors.lastname: Mouritzen Dam
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000015:Abnormalities, Multiple / Q000139:chemically induced; D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D000077213:Lamotrigine; D008297:Male; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D014227:Triazines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine